Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
28.19
+0.46 (+1.66%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Royalty Pharma Plc Cl A
< Previous
1
2
3
4
Next >
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
December 05, 2023
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
NASDAQ:RPRX: good value for what you're paying.
November 14, 2023
Despite its impressive fundamentals, ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) remains undervalued.
Via
Chartmill
Royalty Pharma's Earnings Outlook
November 07, 2023
Via
Benzinga
Why PTC Therapeutics Soared 15% Higher Today
October 19, 2023
The company scored a $1 billion upfront payment for expanding a commercial partnership.
Via
The Motley Fool
2 Dividend Stocks Wall Street Thinks Can Rise by 50%
July 26, 2023
These stocks could give investors the best of both worlds: dividend income and the potential to earn a great profit.
Via
The Motley Fool
$122M Bet On Occidental Petroleum? Check Out These 3 Stocks Insiders Are Buying
June 29, 2023
Although US stocks closed mixed on Wednesday, there were a few notable insider trades.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
June 16, 2023
Friday's session saw 32 companies set new 52-week lows.
Via
Benzinga
$10M Bet On GameStop? Check Out These 3 Stocks Insiders Are Buying
June 14, 2023
Although US stocks closed higher on Tuesday, there were a few notable insider trades.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
September 19, 2023
During Tuesday's session, 275 companies made new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
June 15, 2023
On Thursday, 64 companies achieved new lows for the year.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
September 15, 2023
Friday's session saw 169 companies set new 52-week lows.
Via
Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Earnings Outlook For Royalty Pharma
May 08, 2023
Via
Benzinga
Preview: Royalty Pharma's Earnings
February 14, 2023
Via
Benzinga
Ominous Death Cross Forms On Royalty Pharma's Chart
January 10, 2023
Via
Benzinga
Looking Into Royalty Pharma's Return On Capital Employed
December 06, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 07, 2023
On Thursday, 283 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
May 24, 2023
On Wednesday, 129 stocks made new 52-week lows.
Via
Benzinga
$12.5M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying
May 18, 2023
Although US stocks closed higher on Wednesday, there were a few notable insider trades.
Via
Benzinga
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
May 09, 2023
Via
Benzinga
Insiders Selling TransMedics Group And 2 Other Stocks
February 28, 2023
The Nasdaq 100 closed higher by around 0.7% on Monday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
February 28, 2023
During Tuesday, 79 stocks hit new 52-week lows.
Via
Benzinga
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023
February 27, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Five Best And Worst Performing Healthcare Stocks In December 2022
January 22, 2023
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst...
Via
Talk Markets
6 Stocks Warren Buffett Completely Exited in 2022
December 17, 2022
Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of its holdings as it repositioned its portfolio.
Via
The Motley Fool
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position
October 18, 2022
There may be more trouble on the horizon for these stocks than most investors are seeing right now.
Via
The Motley Fool
Jim Cramer Likes This Biotechnology Stock: 'It's Not Big, But It's Not Bad'
October 14, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Royalty Pharma plc (NASDAQ: RPRX) and will stick with it. "It’s not big, but it’s not bad," he added.
Via
Benzinga
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
September 19, 2022
Via
Benzinga
Royalty Pharma's Return On Capital Employed Insights
August 22, 2022
Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q2 earnings of $491.60 million, an increase from Q1 of 283.81%. Sales dropped to $535.96 million, a 4.63% decrease between quarters.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.